Skip to main content
. 2021 Jan 20;6(2):100653. doi: 10.1016/j.adro.2021.100653

Table 4.

A comparison of putative cumulative dose constraints

OAR α/β This study (EQD2) Paradis et al (EQD2)6 Troost et al (EQD2, 9-mo interval)27 American Radium Society (EQD2)
Spinal cord 2 Dmax 60 Gy D0.1cc <56.25 Gy Dmax <65 Gy Dmax <57 Gy
Esophagus 3 Dmax 75-100 Gy D0.1cc <90.6 Gy Dmax <100 Gy V60 <40%, Dmax <100-110 Gy
Brachial plexus 2 Dmax 80-95 Gy D0.1cc <85 Gy Dmax <85 Gy Dmax <85 Gy
Great vessels 3 Dmax 110 – 115 Gy D0.1cc <123 Gy Dmax <110 Gy Dmax <120 Gy
PBT 3 Dmax <80-105 Gy D0.1cc <90.6 Gy Dmax <110 Gy Dmax <110 Gy
Skin/Chest wall 2.5 ALARA D0.1cc <105 Gy n/a n/a
Heart 2.5 ALARA D0.1cc <85 Gy Dmean <70 Gy V40<50%
Lung 3 Individualized Individualized Dmean <22 Gy V20<40%

Abbreviations: ALARA = as low as reasonably achievable; EQD2 = equieffective dose in 2 Gy fractions; OAR = organs at risk; PBT = proximal bronchial tree.

Dose constraints converted from α/β ratio of 2.5 to the stated α/β ratios in the table to allow ease of comparison; dose constraints derived using a 6- to 12-month interval, with OARs being treated to tolerance in the first treatment.

Dose constraints α/β ratios not quoted in the American Radium Society abstract.

Consensus not reached.